Who We Are
We are a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases.
Deep expertise fuels our team’s pursuit of solutions, giving us a unique scientific, clinical, and commercial edge. Our lead candidate, AD109, aims to revolutionize the treatment of obstructive sleep apnea (OSA) as the first oral therapeutic.
Apnimed envisions a new era where novel oral therapies aim to simplify intervention, expand the reach of diagnosis and treatment, and elevate the health and expectations of everyone in the sleep-related breathing disease community.
Committed to the Community:
The Apnimed Way
Just as sleep-related breathing diseases profoundly disrupt lives, we are driven by a shared purpose to disrupt the treatment paradigm to make positive change happen.
For those who feel unseen and overlooked, we believe everyone with a sleep-related breathing disease deserves restful nights, vibrant days, and improved health through simple, safe, and effective therapies.
I feel so fortunate to work with a team who is so committed to addressing the needs of the OSA community
Ketan Mehta
Head of Product and Engineering, Connected Wearables
Explore Our Clinical Pipeline
We are advancing a portfolio of oral therapeutic candidates for sleep-related breathing diseases.
Apnimed Leadership
Our executive team stands boldly for people living with OSA.